Cell Cure Neurosciences, an Israeli company which develops stem cell based treatments for degenerative diseases, has raised $3.5 million via share swap with BioTime Inc. The investment reflects a company value of $15.1 million for Cell Cure, and assures BioTime an ownership of 62 percent.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments